US action date for Sepracor's anti-epileptic put back
This article was originally published in Scrip
Executive Summary
The US FDA has extended the action date for Sepracor's novel anti-epileptic product Stedesa (eslicarbazepine acetate) by three months, to April 30th, 2010.